Travatan is a branded ophthalmic medication that contains the active ingredient travoprost. It belongs to the therapeutic class of ophthalmic care and is formulated as a sterile eye-drop solution supplied in a 2.5 ml bottle. In Hong Kong, Travatan is a prescription-only product regulated by the Hong Kong Department of Health. The medication is indicated for the reduction of intra-ocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.
Travoprost is a synthetic analogue of prostaglandin F₂α. After instillation into the eye, it binds to prostaglandin FP receptors on the ciliary muscle and the uveoscleral outflow pathway. Activation of these receptors leads to remodeling of the extracellular matrix, which increases the outflow of aqueous humor through the uveoscleral route. The result is a gradual reduction in intra-ocular pressure, typically beginning within a few hours and persisting for 24 hours after a single dose.
Key pharmacologic points:
By enhancing aqueous outflow, travoprost directly addresses the primary pathophysiologic mechanism of primary open-angle glaucoma.
Travatan is approved in Hong Kong for the following indications:
The medication is typically prescribed for adult patients in whom IOP reduction is required to prevent optic nerve damage and preserve visual function.
Current peer-reviewed literature does not provide robust evidence for off-label uses of travoprost beyond its established role in glaucoma management. Consequently, this section is omitted.
When in doubt, patients should discuss their full medical and ocular history with an ophthalmologist.
If any of these effects become bothersome, patients should inform their eye care provider.
Travatan carries a black-box-style warning for potential allergic reactions that may manifest as severe eye pain, swelling, or decreased vision.
Travoprost is administered topically, and systemic drug interactions are rare. However:
Patients should disclose all ophthalmic medications, including over-the-counter eye drops and herbal preparations, to their prescriber.
This article provides educational information about Travatan and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
Yes. Travatan is often prescribed as a single drop in each affected eye once daily. Using the medication in both eyes does not increase systemic exposure because absorption remains minimal.
Persistent conjunctival hyperemia may indicate sensitivity or an adverse reaction. Contact your ophthalmologist for evaluation; they may adjust the treatment plan or recommend an alternative therapy.
It is recommended to remove contact lenses before instilling the drop and wait at least 10 minutes before reinserting them. This reduces the risk of lens contamination and improves drug absorption.
A typical adult dose is one drop per eye daily. One milliliter contains roughly 20 drops, so a 2.5 ml bottle provides about 50 drops-enough for approximately 25 days of treatment for a single eye, or 12-13 days if dosing both eyes.
Yes, but timing matters. Apply Travatan first, wait 5 minutes, then instill other eye drops. This sequence helps ensure optimal absorption of travoprost.
Travoprost does not contraindicate ocular surgery, but surgeons may ask patients to discontinue the medication several days before procedures to minimize intra-operative bleeding or inflammation.
Systemic interactions are rare due to minimal absorption. However, patients taking systemic prostaglandin-related drugs (e.g., certain anti-glaucoma agents) should discuss potential additive effects with their physician.
Evening dosing is preferred because prostaglandin analogues often produce a modest nocturnal IOP reduction that extends throughout the night, aligning with the natural circadian rhythm of intra-ocular pressure.
Travoprost is classified as pregnancy category C; it should be avoided during pregnancy unless the potential benefit outweighs the risk. Women who are pregnant or planning pregnancy should discuss alternative IOP-lowering options with their ophthalmologist.
